Arslan S

References (4)

Title : Synthesis and biological studies of pyrimidine derivatives targeting metabolic enzymes - Korkusuz_2024_Arch.Pharm.(Weinheim)__e2300634
Author(s) : Korkusuz E , Sert Y , Arslan S , Aydin H , Yildirim I , Demir Y , Gulcin I , Koca I
Ref : Arch Pharm (Weinheim) , :e2300634 , 2024
Abstract : Novel synthesized pyrimidine derivatives were investigated against carbonic anhydrase isoenzymes I and II (hCA I and II), acetylcholinesterase (AChE), butyrylcholinesterase (BChE), alpha-glycosidase, and aldose reductase (AR) enzymes associated with some common diseases such as epilepsy, glaucoma, Alzheimer's disease, diabetes, and neuropathy. When the results were examined, novel synthesized pyrimidine derivatives were found to have effective inhibition abilities toward the metabolic enzymes. IC(50) values and K(i) values were calculated for each pyrimidine derivative and compared to positive controls. The synthesized novel pyrimidine derivatives exhibited K(i) values in the range of 39.16 +/- 7.70-144.62 +/- 26.98 nM against hCA I, 18.21 +/- 3.66-136.35 +/- 21.48 nM toward hCA II, which is associated with different pathological and physiological processes, 33.15 +/- 4.85-52.98 +/- 19.86 nM on AChE, and 31.96 +/- 8.24-69.57 +/- 21.27 nM on BChE. Also, K(i) values were determined in the range of 17.37 +/- 1.11-253.88 +/- 39.91 nM against alpha-glycosidase and 648.82 +/- 53.74-1902.58 +/- 98.90 nM toward AR enzymes. Within the scope of the study, the inhibition types of the novel synthesized pyrimidine derivatives were evaluated.
ESTHER : Korkusuz_2024_Arch.Pharm.(Weinheim)__e2300634
PubMedSearch : Korkusuz_2024_Arch.Pharm.(Weinheim)__e2300634
PubMedID: 38772694

Title : Protective Effects of Caffeic Acid Phenethyl Ester on Fluoxetine-Induced Hepatotoxicity: An Experimental Study - Yilmaz_2016_Biomed.Res.Int_2016_1247191
Author(s) : Yilmaz A , Elbey B , Yazgan UC , Donder A , Arslan N , Arslan S , Alabalik U , Aslanhan H
Ref : Biomed Res Int , 2016 :1247191 , 2016
Abstract : Background. The aim of the study was to analyse the effect of caffeic acid phenethyl ester (CAPE) on fluoxetine-induced hepatotoxicity in rats. Materials and Methods. Group I served as control. Group II received CAPE intraperitoneally. Group III received fluoxetine per orally. Group IV received fluoxetine and CAPE. The total antioxidant capacity (TAC), total oxidant status (TOS), oxidative stress index (OSI), and liver enzymes including paraoxonase-1 (PON-1), aspartate transaminase, and alanine transaminase levels were measured. Liver tissues were processed histopathologically for evaluation of liver injury and to validate the serum enzyme levels. Results. An increase in TOS and OSI and a decrease in TAC and PON-1 levels in serum and liver tissues of Group III were observed compared to Groups I and II. After treatment with CAPE, the level of TOS and OSI decreased while TAC and PON-1 increased in serum and liver in Group IV. Histopathological examination of the liver revealed hepatic injury after fluoxetine treatment and reduction of injury with CAPE treatment. Conclusion. Our results suggested that CAPE treatment provided protection against fluoxetine toxicity. Following CAPE treatment with fluoxetine-induced hepatotoxicity, TOS and OSI levels decreased, whereas PON-1 and TAC increased in the serum and liver.
ESTHER : Yilmaz_2016_Biomed.Res.Int_2016_1247191
PubMedSearch : Yilmaz_2016_Biomed.Res.Int_2016_1247191
PubMedID: 27144157

Title : Effect of rivastigmine on regional cerebral blood flow in Alzheimer's disease - Cerci_2007_Adv.Ther_24_611
Author(s) : Cerci SS , Tamam Y , Kaya H , Yildiz M , Arslan S
Ref : Adv Ther , 24 :611 , 2007
Abstract : Cholinesterase inhibitors improve or stabilize cognitive impairment in patients with Alzheimer's disease (AD). The purpose of this study was to detect brain perfusion changes and the effects of rivastigmine, an acetylcholinesterase inhibitor on single photon emission computed tomography (SPECT) before and after treatment. Fifteen patients who fulfilled the clinical criteria for probable AD of mild to moderate severity, as put forth by the National Institute of Neurological and Communicative Disorders and Stroke-Alzheimer's Disease and Related Disorders Association, and as specified by the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, were included in the study. A control group of 15 healthy individuals from the same age and education range was included in the study. Before treatment was begun, Mini Mental State Examination (MMSE) tests were performed on all patients to evaluate cognitive function. All patients underwent baseline SPECT for evaluation of 25 different brain regions. Rivastigmine 3 mg/d was given for the first 4 wk of treatment; the dosage was then increased to 6 mg/d. The MMSE and SPECT were repeated 6 mo after the start of treatment. SPECT findings revealed that rivastigmine did not significantly affect brain perfusion in AD cases except in the inferior frontal lobe, despite stabilization and improvement noted in MMSE scores during treatment. Rivastigmine treatment of patients with AD did not significantly change brain perfusion as seen on SPECT, except in the inferior frontal lobe, but cognitive performance was stabilized or improved during the treatment course. These findings suggest the need for additional, larger studies to investigate the effects of acetylcholinesterase inhibitors on regional cerebral blood flow.
ESTHER : Cerci_2007_Adv.Ther_24_611
PubMedSearch : Cerci_2007_Adv.Ther_24_611
PubMedID: 17660172

Title : Deadly nightshade (Atropa belladonna) intoxication: an analysis of 49 children - Caksen_2003_Hum.Exp.Toxicol_22_665
Author(s) : Caksen H , Odabas D , Akbayram S , Cesur Y , Arslan S , Uner A , Oner AF
Ref : Hum Exp Toxicol , 22 :665 , 2003
Abstract : Deadly nightshade (Atropa belladonna) intoxication has been infrequently reported in both children and adults in the literature. In this article, the clinical and laboratory findings of 49 children with acute deadly nightshade intoxication are reviewed. Our purpose was to enlighten the findings of deadly nightshade intoxication in childhood. The most common observed symptoms and signs were meaningless speech, tachycardia, mydriasis, and flushing. None of the children required mechanical ventilation or died in our series. The patients were categorized into two groups, mild/moderate and severe intoxication. Children with and without encephalopathy were accepted as severe and mild/moderate intoxication, respectively. While 43 children were placed in the group of mild/moderate intoxication, six were in severe intoxication group. We found that meaningless speech, lethargy, and coma were more common, but tachycardia was less common in the severe intoxication group (children with encephalopathy) (P < 0.05). In the treatment, neostigmine was used in all children because of no available physostigmine in our country. In conclusion, our findings showed that the initial signs and symptoms of acute deadly nightshade intoxication might be severe in some children, but no permanent sequel and death were seen in children. We also showed that meaningless speech, lethargy, coma, and absence of tachycardia were ominous signs in deadly nightshade intoxication in childhood. Lastly, we suggest that neostigmine may be used in cases of deadly nightshade intoxication if physostigmine cannot be available.
ESTHER : Caksen_2003_Hum.Exp.Toxicol_22_665
PubMedSearch : Caksen_2003_Hum.Exp.Toxicol_22_665
PubMedID: 14992329